An open-label extension trial of dupilumab for up to three years in adults and adolescents with moderate-to-severe asthma has confirmed the safety and efficacy profile observed in shorter duration phase 2 and 3 studies. The LIBERTY ASTHMA TRAVERSE study, presented at the ERS Virtual Congress, included 2,282 patients who received add-on dupilumab (300 mg every ...
Dupilumab safety and efficacy confirmed in extension study
By Mardi Chapman
10 Sep 2020